The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
 
Shaji Kumar
No Relationships to Disclose
 
Susanna J. Jacobus
No Relationships to Disclose
 
Adam D. Cohen
No Relationships to Disclose
 
Matthias Weiss
No Relationships to Disclose
 
Natalie Scott Callander
No Relationships to Disclose
 
Avina A. Singh
No Relationships to Disclose
 
Terri L. Parker
No Relationships to Disclose
 
Alex R. Menter
No Relationships to Disclose
 
Xuezhong Yang
No Relationships to Disclose
 
Benjamin Marshall Parsons
No Relationships to Disclose
 
Pankaj Kumar
No Relationships to Disclose
 
Prashant Kapoor
No Relationships to Disclose
 
Aaron Seth Rosenberg
No Relationships to Disclose
 
Jeffrey A. Zonder
No Relationships to Disclose
 
Edward Anthony Faber
No Relationships to Disclose
 
Sagar Lonial
No Relationships to Disclose
 
Paul G. Richardson
No Relationships to Disclose
 
Robert Z. Orlowski
No Relationships to Disclose
 
Lynne I. Wagner
No Relationships to Disclose
 
S. Vincent Rajkumar
No Relationships to Disclose